XML 47 R32.htm IDEA: XBRL DOCUMENT v3.19.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Reconciliation of numerator and denominator of basic and diluted EPS
A reconciliation of the numerator and denominator of basic and diluted earnings per share follows (in thousands except share and per share amounts):
 
 
Successor
 
 
 
Predecessor
 
 
Year Ended December 31,
 
September 1 to
December 31,
 
 
 
January 1 to
August 31,
 
Year Ended December 31,
 
 
2018
 
2017
 
 
 
2017
 
2016
 
 
 
 
 
 
 
 
 
 
 
Numerator:
 
 
 
 
 
 
 
 
 
 
Net (loss) income attributable to Surgery Partners, Inc.
 
$
(205,706
)
 
$
(41,316
)
 
 
 
$
(11,669
)
 
$
9,453

Less: amounts allocated to participating securities (1)
 
32,426

 
10,481

 
 
 
—

 
—

Less: mark to redemption adjustment
 
 
 
15,566

 
 
 
—

 
—

Net (loss) income attributable to common stockholders
 
$
(238,132
)
 
$
(67,363
)
 
 
 
$
(11,669
)
 
$
9,453

 
 
 
 
 
 
 
 
 
 
 
Denominator:
 
 
 
 
 
 
 
 
 
 
Weighted average shares outstanding- basic
 
48,027,875

 
48,319,193

 
 
 
48,121,404

 
48,018,944

Effect of dilutive securities (2)
 
—

 
—

 
 
 
—

 
171,794

Weighted average shares outstanding- diluted
 
48,027,875

 
48,319,193

 
 
 
48,121,404

 
48,190,738

 
 
 
 
 
 
 
 
 
 
 
(Loss) earnings per share:
 
 
 
 
 
 
 
 
 
 
Basic
 
$
(4.96
)
 
$
(1.39
)
 
 
 
$
(0.24
)
 
$
0.20

Diluted (2)
 
$
(4.96
)
 
$
(1.39
)
 
 
 
$
(0.24
)
 
$
0.20

 
 
 
 
 
 
 
 
 
 
 
Securities outstanding not included in the computation of diluted (loss) earnings per share as their effect is antidilutive:
 
 
 
 
 
 
 
 
 
 
Stock options
 
82,602

 
—

 
 
 
—

 
—

Restricted shares
 
198,267

 
62,850

 
 
 
105,944

 
—

Convertible preferred stock
 
—

 
—

 
 
 
N/A

 
N/A

(1) Amounts allocated to participating securities includes dividends accrued during the Successor periods for the Series A Preferred Stock. The Series A Preferred Stock does not participate in undistributed losses. There were no participating securities during the Predecessor periods.
(2) The impact of potentially dilutive securities for the year ended December 31, 2018 (Successor), four months ended December 31, 2017 (Successor) and the eight months ended August 31, 2017 (Predecessor), were not considered because the effect would be anti-dilutive in each of those periods.